Intersect Ent Inc
F:7IN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Intersect Ent Inc
F:7IN
|
US |
|
W
|
Winix Inc
KOSDAQ:044340
|
KR |
|
Plastiblends India Ltd
NSE:PLASTIBLEN
|
IN |
|
Optiscan Imaging Ltd
ASX:OIL
|
AU |
|
C
|
Cresud SACIF y A
BCBA:CRES
|
AR |
|
Aumake Ltd
ASX:AUK
|
AU |
|
F
|
Fittech Co Ltd
TWSE:6706
|
TW |
|
C
|
Chu Kai PCL
SET:CRANE
|
TH |
|
N
|
Northern ARC Capital Ltd
NSE:NORTHARC
|
IN |
|
D
|
Doxa AB
STO:DOXA
|
SE |
Intersect Ent Inc
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. The company is headquartered in Menlo Park, California and currently employs 433 full-time employees. The company went IPO on 2014-07-24. The firm's steroid-releasing products are designed to provide mechanical spacing and deliver targeted therapy (mometasone furoate) to the site of disease. These products include its PROPEL family of products (PROPEL, PROPEL Mini and PROPEL Contour) and the SINUVA (mometasone furoate) Sinus Implant. The PROPEL family of products are used in adult patients to reduce inflammation and maintain patency following sinus surgery, primarily in hospitals and ambulatory surgery centers (ASC), with increasing applications in the physician office setting of care in conjunction with balloon dilation and following post-surgical debridement. SINUVA is a physician administered drug, designed to be used in the physician office setting of care to treat adult patients who have had ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company also offers ENT products, such as VenSure and CUBE.
